Post-transplantation Malignancy After Kidney Transplantation in Turkey

• Published in: Transplantation proceedings 2015-06, Vol.47 (5), p.1418-1420
• Main Authors: Keles, Y, Tekin, S, Duzenli, M, Yuksel, Y, Yücetin, L, Dosemeci, L, Sengul, A, Demirbaş, A, Tuncer, M
• Format: Article
• Language: English
• Subjects: Adult; Aged; Breast Neoplasms - epidemiology; Breast Neoplasms - etiology; Cytomegalovirus; Female; Follow-Up Studies; Herpesvirus 4, Human; Humans; Immunosuppressive Agents - administration & dosage; Incidence; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - surgery; Kidney Transplantation - adverse effects; Lung Neoplasms - epidemiology; Lung Neoplasms - etiology; Lymphoproliferative Disorders - epidemiology; Lymphoproliferative Disorders - etiology; Male; Middle Aged; Neoplasms - epidemiology; Neoplasms - etiology; Risk; Skin Neoplasms - epidemiology; Skin Neoplasms - etiology; Surgery; Thyroid Neoplasms - epidemiology; Thyroid Neoplasms - etiology; Turkey; Urogenital Neoplasms - epidemiology; Urogenital Neoplasms - etiology; Viral Load
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2015.04.010

Abstract Objective Kidney transplantation is the best treatment option for end-stage renal disease patients. Increased incidence of post-transplantation malignancy can be caused by immunosuppressive drugs and some oncogenic infections. The aim of this study is to show the incidence of post-transplantation malignancy in patients who had surgery and were followed up in the Organ Transplant Center, Medical Park Antalya, Antalya, Turkey. Method The study was based on 2100 kidney transplantation patients who had surgery between May 2008 and December 2012 and also on 1900 patients who had surgery by members of our team in other centers and who were followed up routinely. In all of our patients, the type of malignancy, the time that malignancy developed, immunosuppressive regimens, and viral status (Epstein-Barr virus and cytomegalovirus) were investigated. Results Malignancy was developed in 30 patients (60% of them were male, median age was 52.1 years). Post-transplantation malignancy development time was a median of 5.1 years. The types of malignancies were as follows: non-melanoma skin cancer in 12 patients (40%), urogenital cancer in 7 patients (24%), breast cancer in 4 patients (14%), lymphoproliferative disease in 3 patients (10%), thyroid cancer in 2 patients (6%), and lung cancer in 2 patients (6%). Discussion In this study, we did not find any increased post-transplantation malignancy risk in our patients. This finding could be due to the low-dosage immunosuppressive protocols that we used.